Diffusion tensor MR to monitor glymphatic system
Systems and methods are contemplated for monitoring and analyzing the glymphatic system and brain to predict, prognose, diagnose, treat, modify or improve treatment, and track progression of neurological diseases. A first and second MRI image are taken of an extracellular space in a region of interest in a patient's brain, with one image taken while the patient is awake and the other image taken while the patient is asleep. The first and second images are compared to detect changes in the extracellular space, and the comparison is used to predict, prognose, diagnose, treat, modify or improve treatment, and track progression of neurological diseases associated with the extracellular space.
1. A method of treating a neurological disease in a region of a patient's brain, comprising:
taking a first image and a second image of the region of the patient's brain via magnetic resonance imaging (MRI);
comparing the first image with the second image to detect a change in an extracellular space in the region of the patient's brain;
administering a therapeutic agent responsive to the neurological disease when, during a time period, the change in the extracellular space indicates increased exposure of the therapeutic agent to the region of the patient's brain; and
administering a secondary agent that increases or decreases the change in the extracellular space;
wherein the first image is taken while the patient is awake, the second image is taken while the patient is asleep, and the first and second images are taken less than thirty minutes apart.
2. The method of claim 1 , wherein the MRI is diffusion tensor imaging (DTI).
3. The method of claim 2 , wherein the first and second images quantify the extracellular space and an intracellular space proximal to the extracellular space.
4. The method of claim 2 , wherein the first and second images quantify free water in the extracellular space.
5. The method of claim 1 , wherein the first and second images are taken less than ten minutes apart.
6. The method of claim 1 , wherein the second image is taken while the patient is in slow-wave sleep.
7. The method of claim 1 , wherein the second image is taken after the patient is artificially induced into sleep.
8. The method of claim 7 , wherein the patient is artificially induced into sleep using dexmedetomidine.
9. Use of the method of claim 1 to assess a condition of the patient's glymphatic system.
10. The method of claim 1 , wherein the change is an increase in extracellular space in the region of the patient's brain.
11. The method of claim 10 , wherein the secondary agent increases the change to thereby improve delivery of the therapeutic agent to the region of the patient's brain.
12. The method of claim 10 , wherein the secondary agent decreases the change to thereby reduce delivery of the therapeutic agent to the region of the patient's brain.
13. The method of claim 1 , wherein the first and second images are taken less than five minutes apart.
14. The method of claim 1 , wherein the first and second images are taken less than ten minutes apart and the second image is taken after the patient is artificially induced into sleep.
15. The method of claim 1 , wherein the secondary agent is administered in conjunction with the therapeutic agent.
16. The method of claim 1 , wherein the therapeutic agent is delivered via cerebrospinal fluid.